Применение левофлоксацина в пульмонологии
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Полный текст:
Об авторах
С. В. ЯковлевРоссия
Москва
В. П. Яковлев
Россия
Москва
Список литературы
1. Tilloston G.S., Blondeau J.M. Today’s community respiratory tra c t infections: a challenge appropriate for moxifloxacin. In: Adam D., Finch R., eds. Moxifloxacin in practice. Oxford: Maxim Medical; 1999; Voll: 1 - 11.
2. Яковлев С.В. Сравнительная оценка беталактамов и макролидов при внебольничных респираторных инфекциях. Антибиотики и химиотер. 2001; 46 (3): 1-4.
3. Sahm D. Pre-clinical microbiology - respiratory tra c t infections susceptibility survey - USA. In: Mandell L., ed. First International moxifloxacin symposium. Berlin: Springer Verlag; 2000; 54-58.
4. Schmitz F.J., Verhoe[ J., Fluit A.C. Comparative activities of 27 antimicrobial compounds against 698 Streptococcus pneumoniae isolates. In: J.Antimicrob. Chemother.1999; 44 (suppl. A): Abstr. N P 199.
5. Tavanic (levofloxacin) IV /o ra l. Scientific Product Monograph. - Hoechst Marion Roussel.
6. Barry A.L., Fuchs P.C., Allen S.D. In vitro susceptibilityu of Streptococcus pneumoniae to the d- and 1-isomers of ofloxacin: interpretive criteria and quality control limits. J.Antimicrob. Chemother. 1996; 37: 365-369.
7. Yamane Y., Jones R.N., Frei R. et al. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J.Chemother. 1994; 6: 83-91.
8. Baltch A.L., Smith R.P., Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampicin used singly and in combination against Legionella pneumophila. Antimicrob. Agents. Chemother. 1995; 39: 1661-1666.
9. Molitoris E., Wexler H.M., Finegold S.M. In vitro activity of levofloxacin against bacteria from skin and soft tissue infections. In: 36th Intersciences conferense on antimicrobial agents chemotherapy. New Orleans; 1996. Abstr. N E88.
10. Goldstein E.J.C., Nesbit C.A., Citron DM. Comparative in vitro activities of azithromycin, Bay у 3118, levofloxacin, sparfloxacin, and 11 other oral anti-microbial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob. Agents Chemother. 1995; 39: 1097-1100.
11. Child J., Mortiboy D., Andrews J.M. et al. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluids. Ibid. 2749-2751.
12. Lee L.J., Sha X., Gotjried M. et al. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy 1998; 180: 35-41.
13. Gaja М., Higa F., Yamashiro T. et al. Penetration of levofloxacin, a new quinolone antibacterial agent, inti to human neutrophils. Chemotherapy (Tokyo) 1992; 40 (suppl.3): 64-67.
14. Taira K., Toga H., Kohno S. Accumulastion of a newly developed fluoroquinolone, OPC-17116, bay human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 1993; 37: 1877-1881.
15. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N. Engl. J. Med. 1995; 333: 1618-1624.
16. Fass R.J. Aetiology and tre a tm en t of community-acquired pneumonia in adults: an historical perspective. J. Antimicrob. Chemother. 1993; 32 (suppl. A): 17-27.
17. Marrie T.J. Community-acquired pneumonia. Clin. Infects. Dis. 1994; 18: 501-513.
18. Marrie T.J., Peeling R.W., Fine M.J. et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical ag ents and clinical course. Am.J. Med. 1996; 101: 508-515.
19. Fogarty C.M., Sullivan J.G., Chattman M.S. et al. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect.Dis.Clin.Pract. 1998; 7: 400-407.
20. Kahn J.B., Wiesenger B.A., Williams R.R. Levofloxacin in the treatment of community-acquired pneumonia due to penicillin- and macrolide-resistant pneumococci. In: 39th Intersciences conference antimicrobial agents chemotherapy. San Francisco; 1999. 12.
21. Wiesenger B.A., Kahn J.B., Morgan N. Efficacy of levofloxacin in the treatment of community-acquired pneumonia due to macrolide resistant Streptococcus pneumoniae. In: 5th International conference macrolides, azalides, streptogramins, ketolides and oxazolidinones. Seville; 2000. Abstr. N 423.
22. File T.M. Levofloxacin in the trea tm en t of community-acquired pneumonia. Clin. Respir. J. 1999; 6 (suppl. A): 35A-39A.
23. Kahn J.B., Wiesenger B.A., Oross M.P. et al. Levofloxacin versus azithromycin plus ceftriaxone in moderate to severe communityacquired pneumonia (CAP). In: 5th International conference on macrolides, azalides, streptogramins, ketolides and oxazolidinones. Seville; 2000. Abstr. N 424.
24. Carbon C., Ariza H., Rabie W.J. et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mildto-moderate community-acquired pneumonia. Clin. Microbiol. Infect. 1999; 5: 724-732.
25. Gottfried M., Sullivan J.G., Mayer H. et al. A randomised, double-blind, multicenter, comparative study of gatifloxacin (GAT) vs levofloxacin (LEV) in treatment of community-acquired pneumonia (CAP). In: 39th Intersciences conference antimicrobial agents chemotherapy. San Francisco; 1999. Abstr. N 2243.
26. Williams R.R., Fogarty C., Dunbar L. et al. The efficacy of levofloxacin in the treatment of community-acquired pneumonia due to Mycoplasma pneumoniae or Chlamydia pneumoniae. Clin. Infect. Dis. 1998; 27: Abstr. N 168.
27. Hammerschlag M.R., Robbin P.M. Microbiology efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob. Agents Chemother. 2000; 44 (5): 1409.
28. Williams R.R., Stout J.E., Yu R.N. et al. Levofloxacin is safe and effective in the management of community-acquired pneumonia (CAP) due to Legionella. In: 6th International symposium on new quinolones. Denver; 1998. Abstr. N 96.
29. Hammerschlag M.R., Reznik T.t Robin P. Microbiology efficacy of levofloxacin for the treatment of serious community-acquired pneumonia due to Chlamydia pneumoniae. J.Antimicrob. Chemother. 2001; 41 (suppl. SI ) : Abstr. P 112.
30. Kahn J.B., Wiesenger A., Olson W.H. et al. Levofloxacin vs. ceftriaxone sodium and erythromycin in th trea tm en t of patients with community-acquired pneumonia (CAP) at high risk of mortality. Ibid. Abstr. N P 115.
31. O’Hare M., Harding I. Levofloxacin therapy for community-acquired pneumonia due to atypical and intracellular microorganisms. Abstr. N P 119.
32. Harding I., O’Hare M. Levofloxacin for the trea tm en t of community-acquired pneumonia: clinical advantages over other empiric therapies. Ibid. Abstr. N P 121.
33. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest l995 ; 108 (supp l.1): 4 3S-52S.
34. Anthonisen N.R., Manfreda J., Warren C.P.W. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.
35. Burley C.J., Masterton R.G. A double-blind comparison of oral levofloxacin 500 mg once daily for 7 days in patients with acute exacerbation of chronic bronchitis. Clin. Microbiol. Infect. 1999; 5 (suppl.3): 276, Abstr. N P 715.
36. Shah P.M., Maesen F.P. V., DolmannA. et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomised, double-blind study. J.Antimicrob. Chemother. 1999; 43: 529-539.
37. Davies B.I., Maesen F.P.V. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. Ibid. (suppl. C): 83-90.
Рецензия
Для цитирования:
Яковлев С.В., Яковлев В.П. Применение левофлоксацина в пульмонологии. Пульмонология. 2001;(3):76-83.
For citation:
Yakovlev S.V., Yakovlev V.P. Application of Levofloxacin in pulmonology. PULMONOLOGIYA. 2001;(3):76-83. (In Russ.)
ISSN 2541-9617 (Online)